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Available online 4 December 2007Serotonin (5-HT) system has a significant role in anxiety- and depression-related states and
may be influenced by brain-derived neurotrophic factor (BDNF). This study examined
extracellular 5-HT levels andexpressionof BDNF in ratswithpersistently loworhigh levels of
exploratory activity (LE and HE, respectively). Baseline extracellular levels of 5-HT as
assessed by in vivomicrodialysis in conscious animals were similar in both groups inmedial
prefrontal cortex (PFC) and dentate gyrus (DG). No differences were found in
parachloroamphetamine-induced 5-HT release in either region. However, LE animals had
significantly higher levels of 5-HT transporter (5-HTT) binding in PFC and a larger increase in
extracellular 5-HT levels after administration of citalopram (1 μM) into this area by retrograde
dialysis. No difference in 5-HTT levels was found in hippocampus, while perfusion with
citalopram was accompanied by a greater increase in extracellular 5-HT in the HE group in
this brain region. LE-rats hadhigher levels of BDNFmRNA in the PFCbut not hippocampus. In
contrast, levels of nerve growth factor mRNA were similar in these brain regions of LE- and
HE-rats. The differential regulation of 5-HT-ergic system in LE- and HE-rats in PFC and
hippocampus may form the basis for their distinct anxiety-related behaviours.








The serotonergic systemhas been implicated in the etiology of
human affective and anxiety disorders and is a major target in
the treatment of these conditions (Morilak and Frazer, 2004). It
has also been proven to play a role in anxiety and emotionalro).
loratory activity; HE, high
; 5-HTT, serotonin transp
eral; DV, dorsal–ventral
CC BY license.reactivity in animals and in corresponding animal models of
human disorders (for a review, see Griebel, 1995). Never-
theless, serotonin (5-HT) pathways do not have a unitary
function in modulating anxiety. In general, the influence of 5-
HT neurons on forebrain centers has been suggested to
facilitate threat-related information processing, while the 5-exploratory activity; PFC, prefrontal cortex; DG, dentate gyrus; HI,
orter; BDNF, brain-derived neurotrophic factor; NGF, nerve growth
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(Handley, 1995). 5-HT-ergic pathways innervating such brain
regions as the frontal cortex, amygdala, hypothalamus and
hippocampus have been found to be activated by anxiogenic
stimuli, including psychosocial stress, conditioned fear and
conflict procedures (for a review see Millan, 2003). The
relationship between 5-HT-ergic activity and the affective
state of the test animal is not always straightforward, as it has
also been shown that an increase in 5-HT-ergic activity in
different forebrain regions may be linked simply to general
behavioural activity but not to specific actions or affective
states (Rueter and Jacobs, 1996). Both reduced as well as
increased 5-HT-ergic neurotransmission have been associated
with negative emotionality (see Tõnissaar et al., 2004, and
references therein).
Animals bred or preselected based on anxiety-related
behaviour in one test often but not always display
consistently different behavioural patterns in other tests
used in anxiety and depression research (Kabbaj et al., 2000;
Ho et al., 2002; Mällo et al., 2007a). Differences in the
expression of anxiety are accompanied by differences in
neurochemistry of amino acids, monoamines and neuro-
peptides (Rägo et al., 1988; Harro et al., 1990; Landgraf, 2005;
Singewald, 2007). Particular interest has been paid to the 5-
HT-ergic function in medial prefrontal cortex (PFC) and
hippocampus (Pollier et al., 2000; Giorgi et al., 2003; Keck et
al., 2005), but the results have remained rather inconclusive,
possibly due to large variation in behavioural paradigms
and methods used and the single variables measured. In
our laboratory, we have used a test of exploratory behaviour
(Otter et al., 1997) which usually yields a rather dichot-
omous distribution of rats into groups with low and high
exploratory activity (LE and HE, respectively) with high
reliability to predict further novelty-related activities (see
Mällo et al., 2007a). We have shown that these two groups
display, respectively, high and low levels of anxiety in
several other behavioural tests and respond differently to
certain pharmacological manipulations. For example, treat-
ment with the neurotoxin DSP-4 which is selective to the
locus coeruleus noradrenergic projections had different
effects on spontaneous, amphetamine-stimulated (Alttoa
et al., 2005) and amphetamine-sensitized (Alttoa et al.,
2007) behaviour in LE- and HE-rats. DSP-4 treatment also
decreased the ex vivo 5-hydroxyindoleacedic acid levels in
the nucleus accumbens and striatum in LE-rats only. We
have also found that the HE-rats have higher extracellular
dopamine levels in the striatum in baseline conditions as
well as in response to amphetamine administration, while
no difference was detected in the nucleus accumbens (Mällo
et al., 2007a). In the light of the importance of 5-HT-ergic
system in the anxiety- and depression-related conditions
we have studied the LE- and HE-rats regarding their 5-HT
extracellular levels in PFC and hippocampus (in case of
microdialysis studies the target was more specifically
dentate gyrus (DG)) in baseline conditions, after systemic
administration of the 5-HT-releasing agent parachloroam-
phetamine (PCA) and after local infusion of 5-HT reuptake
inhibitor citalopram. Also, 5-HT transporter (5-HTT) levels
were measured in the same brain regions by radioligand
binding.Neurotrophins, including nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF), neurotrophin-3
and neurotrophin-4, are a family of secreted growth factors
that promote the survival, differentiation and maintenance
of specific neuronal populations and regulate activity-
dependent synaptic plasticity (reviewed in Bibel and Barde,
2000). Decreases of BDNF levels are accompanied by and are
believed to lead to several pathologies, including neuropsy-
chiatric disorders like anxiety-related behaviours, depres-
sion, bipolar disorder, schizophrenia and neurodegenerative
disorders like Huntington's, Parkinson's and Alzheimer's
diseases (reviewed in Binder and Scharfman, 2004; Angelucci
et al., 2005; Duman and Monteggia, 2006). Because the
promotion of the function and growth of 5-HT-ergic neurons
by BDNF (Mamounas et al., 1995; Altar, 1999), as well as
changes in BDNF function in affective disorders (Licinio and
Wong, 2002) have been described, we also measured the
levels of BDNF expression in these brain regions in LE- and
HE-rats.2. Results
2.1. Baseline extracellular 5-HT levels in LE- and HE-rats,
and the effect of PCA
In the baseline conditions, the average (mean±SEM of
samples 4.–6.) extracellular levels of 5-HT were 10.2±
3.4 fmol/22.5 μl sample in the LE-rats and 5.8±1.1 fmol/
22.5 μl sample in the HE-rats in PFC and 1.95±0.27 fmol/22.5 μl
sample in the LE rats and 1.97±0.34 fmol/22.5 μl sample in the
HE-rats in DG. Repeated measures ANOVA revealed no
difference between LE and HE groups in baseline 5-HT levels
in either region. The increase in extracellular 5-HT availability
after administration of PCA (2 mg/kg) was also similar in both
regions in both groups (Fig. 1).
2.2. 5-HTT levels in LE- and HE-rats
In PFC, a significant difference between the groups in 5-HTT
binding (t=−2.97; P<0.05) was found, with the transporter
levels significantly higher in the LE group (Fig. 2). In the
hippocampus, no difference was detected in 5-HTT levels
between the two groups.
2.3. Effect of citalopram administration on extracellular
5-HT availability in LE- and HE-rats
In the baseline conditions, the average (mean±SEM) extra-
cellular levels of 5-HT in PFC were 6.95±2.16 fmol/22.5 μl
sample in the LE-rats and 5.02±0.55 fmol/22.5 μl sample in the
HE-rats, and in DG, 9.71±2.33 fmol/22.5 μl sample in the LE-
rats and 10.81±2.22 fmol/22.5 μl sample in the HE-rats. There
were no significant differences in extracellular 5-HT levels in
either PFC or DG in baseline conditions. A significant
difference between LE and HE groups was found in both PFC
[F(1,10)=5.30; P<0.05] and DG [F(1,10)=6.44; P<0.05] (Figs. 3A
and B, respectively), when citalopram (1 μM)was administered
via reverse dialysis. In PFC, the increase in extracellular 5-HT
levels after citalopram infusion was about twofold higher in
Fig. 3 – Extracellular serotonin levels in the medial prefron-
tal cortex (A) and dentate gyrus (B) of LE- and HE-rats, after
local infusion of citalopram. Samples were collected every
15 min and are presented as percentage of baseline levels
(mean of samples 4.–6.). Infusion with 1 μM solution of
citalopram was made during the collection of samples 7.–16.
∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.0001 difference between LE and HE
groups. LE – low exploratory activity rats (filled squares, n=6
in both regions); HE – high exploratory activity rats (open
squares, n=6 and 7 in PFC and HI, respectively).
Fig. 1 – Extracellular serotonin levels in the medial prefrontal
cortex (A) and dentate gyrus (B) of LE- and HE-rats after
parachloroamphetamine (PCA) treatment. Samples were
collected every 15 min and are presented as percentage of
baseline levels (mean of samples 4.–6.). PCA (2 mg/kg,
intraperitoneally) was administered before the collection of
sample 8. LE – low exploratory activity rats (filled squares, n=4
and 9 in PFC andHI, respectively); HE – high exploratory activity
rats (open squares, n=6 and 10 in PFC and HI, respectively).
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DG, the increase in 5-HT levels after citalopram infusion was
about two times higher in the HE-rats than the LE-rats.Fig. 2 – 5-HTT levels measured with [3H]citalopram binding
in membranes of the medial prefrontal cortex (PFC) and
hippocampus (HI) of LE- and HE-rats. ∗P<0.05 compared to
the HE group. LE – low exploratory activity rats (filled bars,
n=6 in both regions); HE – high exploratory activity rats (open
bars, n=6 and 7 in PFC and HI, respectively).2.4. Neurotrophin mRNA levels in LE- and HE-rats
In the PFC, a significant effect of Exploration was revealed on
the BDNF mRNA levels normalized with β-actin [F(1,18)=8.48;
P<0.01] that were higher in the LE group in the left hemi-
sphere; there was no exploration× left/right hemisphere
interaction in ANOVA and indeed a similar difference between
the LE and HE groups in the right hemisphere which missed
the conventional level of significance was also notable (Fig. 4).
No differences in BDNF mRNA levels were found between LE
and HE animals in hippocampus. Also, no differences in NGF
mRNA levels were found between LE and HE animals in either
brain region.3. Discussion
The present results demonstrate that there are differences in
the 5-HT-ergic system in frontal cortex and hippocampus
between rats preselected in the exploration box test for low
Fig. 4 – Relative levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) mRNA in prefrontal cortex
(PFC) and hippocampus (HI) of LE- and HE-rats separately in left and right hemisphere: (A) BDNF in PFC; (B) NGF in PFC; (C) BDNF
in HI; (D) NGF in HI. BDNF and NGF mRNAwere normalized to β-actin. ∗P<0.05 difference compared to the respective LE group.
LE – low exploratory activity rats (filled bars, n=5–6); HE – high exploratory activity rats (open bars, n=5–6).
113B R A I N R E S E A R C H 1 1 9 4 ( 2 0 0 8 ) 1 1 0 – 1 1 7and high exploratory activity. Both of these regions have been
acknowledged to play significant roles in affective states in
humans and are targets for treatments of mood disorders. The
PFC has widespread influences on multiple components of
forebrain circuits regulating anxiety states and anxiety-
related behaviour. The hippocampal 5-HT-ergic system has
been acknowledged tomediate an anxiogenic response (for an
example, see File et al., 2000), and dysfunction in hippocampal
region, especially in DG, has been ascribed an important role
in stress reactions (Hindmarch, 2002).
In the present experiments, the baseline levels of 5-HT
release in PFC and DG were similar in LE- and HE-rats, and
no differences were detected in PCA-induced depolarization-
independent 5-HT release in these regions. Previously, we
have studied tissue levels of 5-HT and its metabolite in these
regions and found no differences between the two groups
either (unpublished data). Nevertheless, after local infusion
with citalopram, the increase in extracellular 5-HT levels in
LE group was greater in the PFC and smaller in DG. It is
possible that the firing rate of the 5-HT-ergic projections to
the PFC is higher in LE-rats, resulting in higher extracellular
5-HT levels after blockade of 5-HTT, while at baseline
conditions the greater release of 5-HT is balanced by the
increased re-uptake in the LE-rats that we found to have
higher levels of 5-HTT in this region. Similarly, in studies onpatients with bipolar disorder, 5-HTT levels have been found
to be increased in medial prefrontal cortex, but not in
hippocampus (Cannon et al., 2006).
Giorgi et al. (2003) have previously reported higher levels
of [3H]-citalopram binding to 5-HT reuptake sites and
greater increase in 5-HT availability elicited by local
application of chlorimipramine and fluoxetine in the
frontoparietal cortex in Roman high-avoidance rats, that
also have been found to be more anxious in the elevated
plus-maze and light/dark compartment test (Chaouloff
et al., 1994), while the release of 5-HT was similar at
baseline conditions with the low-avoidance (LHA) rats.
Parenthetically, it should be noted that the above men-
tioned high-avoidance rats are also more susceptible to
drugs of abuse than the LHA rats (Giorgi et al., 2007), and
this may also be the case for our LE-rats which develop
sensitization to a low dose of amphetamine that did not
elicit this behavioural change in HE-rats (Alttoa et al., 2007).
Petty et al. (1994) have shown that after exposure of rats to
tail-shock stress, 5-HT release in the medial frontal cortex
correlates significantly with subsequent helpless behaviour,
although the basal 5-HT levels did not. It therefore seems
that the increased reuptake of 5-HT in prefrontal cortical
areas may develop in anxious subjects to reduce beha-
vioural consequences of aversive stimuli.
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levels in hippocampus between Lewis and spontaneously
hypertensive rats, of which the former is more anxious in the
elevated plus-maze test. However, the Wistar-Kyoto rats,
considered as more anxious, have been reported to have
lower levels of 5-HTT binding sites in the hippocampus when
compared with the less anxious spontaneously hypertensive
rats (Pollier et al., 2000), and animals that are bred for high
anxiety-related behaviour in the elevated plus-maze show an
increased number of 5-HTT binding sites in the hippocampus
(Keck et al., 2005). In the context of these controversial
findings, the current results about no difference in hippocam-
pal 5-HTT levels between LE- and HE-animals suggest that
although the 5-HTT in this brain region may have a role in the
regulation of anxiety-related aspects of behaviour, its effects
are regulated by factors possibly not controlled for in these
experiments. It certainly has to be noted that in the current
experiments, 5-HTT levels were measured in the whole
hippocampus of animals not subjected to microdialysis,
while 5-HT availability in the presence of citalopram was
measured by microdialysis in the DG only. Nevertheless, a
possible mechanism for increased 5-HT levels in this region in
HE-rats after local infusion of citalopram may be through
differential activity of 5-HT1B autoreceptors, which regulate
the release of 5-HT by inhibitory feedback and have been
hypothesized to be supersensitive in depression and anxiety
(Moreta and Briley, 2000). The 5-HT1B autoreceptor activity has
previously been found to be different in PFC and DG (Adell et
al., 2001), and indeed in our experiments the effect of local
administration of citalopramon 5-HT levelswasmuch smaller
in DG than in the PFCwhichmay suggest higher degree of local
regulation in this brain region.
It has been previously proposed that 5-HTT-mediated
increases in 5-HT-ergic neurotransmission upregulate BDNF
expression via increases in cAMP response element binding
protein phosphorylation (Duman et al., 1997, 1999; Nibuya et
al., 1996), but it has also been demonstrated that male and
female mice with partial (5-HTT +/−) or complete (5-HTT −/−)
reductions in 5-HTT expression have no differences in BDNF
protein levels in frontal cortex and striatum, as compared to 5-
HTT +/+ mice (Szapacs et al., 2004), suggestive that at least the
regions studied lack 5-HTT-mediated control over this neuro-
trophin system. Apparently, the decreased BDNF levels are
accompanied by rather subtle changes in the 5-HT system that
may not be significant at baseline conditions (i.e. in micro-
dialysis studies), but which nevertheless become substantial
in more challenging conditions. For an example, when BDNF
+/− mice were interbred with 5-HTT knock-out mice, the lack
of either gene on its own had no significant effect on
behaviour in the elevated plus-maze test, but the combined
effects of partially or totally knocking out both genes
significantly decreased activity on the open arms (Ren-
Patterson et al., 2006). In the present experiments, the levels
of BDNF mRNA were found to be higher in the PFC of the LE-
rats as compared to the HE-rats, suggesting that BDNF gene
expression is increased on the level of transcription or mRNA
stability. NGF mRNA levels were found not to be different in
these two groups. This, combined with the current results
from the microdialysis study in PFC, fits with the findings of
BDNF going hand in hand with increased 5-HT availability(Altar, 1999), possibly through a 5-HTT-controlled process.
Nevertheless, it should be acknowledged that our results are
not indicative of any direct association between BDNF and 5-
HTT expression.
The results contradict with the common BDNF hypothesis
of depression that predicts decreased levels of BDNF mRNA in
depression-related brain areas (Licinio and Wong, 2002).
However, this view is already questioned, as bulbectomized
mice that have depressed-like phenotype have recently been
found to have significantly increased levels of BDNF protein in
hippocampus and frontal cortex (Hellweg et al., 2007). Also, in
two rat models of depression-like states, no differences as
compared to controls or even an upregulation of BDNF has
been found in several brain areas (Angelucci et al., 2004;
Vollmayr et al., 2001). These results suggest that the role of
this neurotrophic factor in mood disorders is more complex
than originally thought. For example, the possibility has to be
considered that the change in BDNF levels in rodent models of
anxiety and depression might indicate an attempt towards
neurochemical adaptation that remains unsuccessful in
behavioural regulation.
The current results suggest that the persistently different
profiles of anxiety-related behaviour can be related to the
differences in the functional qualities of the 5-HT systems in
prefrontal cortex and hippocampus. The increased BDNF
mRNA levels in HE-rats may be influencing or elicited by
these differences between the groups.4. Experimental procedures
4.1. Animals
In all experiments, male Wistar rats (Scanbur BK AB, Sweden)
were housed in groups of four in standard transparent
polypropylene cages under controlled light cycle (lights on
from 08:00 h to 20:00 h, the lighting in the animal room was
320–400 lx, depending on the height of the shelf on which the
cage was located) and temperature (19–21 °C), with free
access to tap water and food pellets (diet R70, Lactamin,
Sweden). In the microdialysis experiment, only data from the
animals with correct probe location are presented. The
experimental protocol was approved by the Ethics Committee
of the University of Tartu.
4.2. Exploration box test
The exploration boxwas carried out as described inMällo et al.
(2007a). The rats were divided into LE and HE activity groups
based on the median value of the sum of exploratory activity
during the second testing. The average scores of exploratory
activity varied between 0 – 6 and 92 – 178 activity units for LE
and HE animals, respectively, over all experiments.
4.3. Microdialysis
Twenty-five LE-rats and 29 HE-rats were subjected to the
microdialysis procedure. The microdialysis probe was
inserted into the left hemisphere PFC in 10 LE and 12 HE
animals and into the left hemisphere DG in 15 LE and 17 HE
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weeks following the second exploration box test. The animals
were anaesthetized with chloral hydrate (350 mg/kg intraper-
itoneally) and mounted in a Kopf stereotactic frame. A self-
made concentric Y-shaped microdialysis probe with 5 mm
shaft length and active membrane on the whole length was
implanted into the PFC according to the following coordi-
nates: AP, +3.3; ML, +0.8; DV, −5.0, according to Paxinos and
Watson (1986). A probe with 4 mm shaft length and 1 mm
active tip was implanted into DG with the following coordi-
nates: AP, −4.3; ML, +2.2; DV, −3.8. The dialysis membrane
used was polyacrylonitrile/sodium methalyl sulphonate
copolymer [Filtral 12; inner diameter (ID), 0.22 mm; outer
diameter, 0.31 mm; AN 69, Hospal, Bologna, Italy]. Two
stainless steel screws and dental cement was used to fix the
probe to the scull. After the surgery, rats were placed in
21×36×18 cm individual cages in which they remained
throughout the rest of the experiment. Rats were given
about 24 h for recovery and microdialysis procedure was
conducted in awake and freely moving animals as described
in Mällo et al. (2007a). We have not detected any significant
effects of the surgery and probe implantation on the animals'
behaviour in our previous studies. In short, after connecting
the animal to the microdialysis system, the perfusate was
discarded during the first 60 min to allow stabilization. Then 6
or 7 samples were collected for analysis, followed by either
intraperitoneal injection of PCA (2 mg/kg, in 4 LE and 6 HE
animals with microdialysis probe in the PFC and in 9 LE and
10 HE animals with microdialysis probe in the DG), or local
administration of citalopram (1 μM) by reverse dialysis for
2.5 h (in the PFC of 6 LE and 6 HE animals and in the DG of 6 LE
and 7 HE animals). Following the PCA injection, another 18
samples were collected; 14 samples were collected after the
cessation of citalopram administration. The samples were
collected in 15-min periods directly into a 50-μl loop of the
electrically actuated injector (Cheminert C2V, Vici AG Inter-
national, Switzerland) and injected automatically into the
column in order to determine the quantity of 5-HT in the
samples online by using HPLC with electrochemical detection.
Upon completion of the experiment the animals were
deeply anesthetized with chloral hydrate (350 mg/kg, intra-
peritoneally) and decapitated; the brains were removed,
immediately frozen and kept at −80 °C. The brains were
sectioned on a cryostatic microtome (Microm GmbH, Ger-
many) and probe placements were determined according to
the atlas of Paxinos and Watson (1986).
4.4. Radioligand binding
Samples from the frontal cortex of 6 LE-rats and 6 HE-rats,
and from the hippocampi of 6 LE-rats and 7 HE-rats were
collected for the determination of 5-HTT levels by specific
binding of [N-methyl-3H]citalopram as described in Mällo
et al. (2007b). The PFC samples were collected from the right
hemisphere (contralateral to the microdialysis site) of the
frozen brains of the animals that had undergone the
microdialysis experiment immediately before the probe
localization determination, while the DG samples were
collected from the right hemisphere of naive animals that
were decapitated and brains immediately dissected on ice.4.5. RNA isolation, cDNA synthesis and quantitative
real-time PCR
Brain regions of six LE-rats and six HE-rats, not used in any
experiments but for the selection, were dissected and used for
total RNA isolation and cDNA synthesis as described pre-
viously (Pruunsild et al., 2007). Levels of total BDNF and NGF
mRNA were quantified with qPCR Core kit for SYBR® Green I
No ROX (RT-SN10-05NR, Eurogentec, Belgium). All reactions
were performed on LightCycler 2.0 thermocycler (Roche) using
the following temperature cycling conditions: 10 min at 95 °C
(initial denaturation step), then 45 cycles of 5 s at 95 °C, 10 s at
55 °C and 10 s at 72 °C. All PCR reactions were performed in
triplicate and normalized to β-actin (ACTB) mRNA levels. The
following primers were used: BDNF_cod_s GGCCCAACGAA-
GAAAACCAT, BDNF_cod_as AGCATCACCCGGGAAGTGT,




Results of the microdialysis experiments are expressed as a
percentage of basal 5-HT values. Basal 5-HT values were
calculated for every individual animal as the mean of the last
three consecutive baseline samples before the start of
citalopram or PCA administration. The data were analysed
with repeated measures ANOVA. Data of the 5-HTT binding
were analysed by means of non-linear least squares regres-
sion using a commercial program GraphPad PRISM™ (Graph-
Pad, San Diego, CA, USA) and obtained parameters compared
with t-tests. Q-PCR data are expressed as BDNF or NGF mRNA
levels relative to the reference β-actin mRNA levels, with the
expression level of 1.0 for a randomly selected sample, and
analysed with a two-factor (exploration×left/right hemi-
sphere) ANOVA. When appropriate, post-hoc comparisons
were made with the Fisher's PLSD test. Statistical significance
was set at P<0.05 in all analyses. All statistics were made
using StatView 5.0 software (SAS Institute Inc., Cary, NC, USA).Acknowledgments
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